Keros Therapeutics Updates Corporate Presentation (Regulation FD)

What Happened
Keros Therapeutics, Inc. announced on August 3, 2026 that it updated its corporate presentation for use in meetings with investors, analysts and others. The presentation dated August 2026 was furnished as Exhibit 99.1 to a Current Report on Form 8‑K and is available on the company’s website. The company stated the information is being furnished (not “filed”) and therefore is not subject to liability under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings absent specific reference.

Key Details

• Date filed: August 3, 2026 (Form 8‑K, Item 7.01 Regulation FD disclosure).
• Exhibit: Corporate Presentation dated August 2026 furnished as Exhibit 99.1.
• Availability: Presentation posted on Keros’ website for investors, analysts and others.
• Legal note: Information is furnished, not filed, and not incorporated by reference into other SEC filings unless expressly stated.

Why It Matters
An updated corporate presentation is a direct way management shares the latest corporate overview, strategy, program status and investor messaging. Because it was furnished under Regulation FD, the material was broadly disseminated to the market rather than provided selectively. Investors should review Exhibit 99.1 on Keros’ website or in the 8‑K filing for any updates to program timelines, clinical or business highlights, or messaging that could affect investment decisions.